prnewswire.com · 9 jul

Illumina to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026

SAN DIEGO, July 9, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the second quarter 2026 following the close of market on Thursday, July 30, 2026. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.

zacks.com · 9 jul

Stocks Look Shaky, But This Sector is Booming (Biotech)

Biotechnology stocks like Illumina, Eli Lilly and Exelixis have quietly turned into the new market leaders.

zacks.com · 9 jul

Illumina (ILMN) Is Up 6.87% in One Week: What You Should Know

Does Illumina (ILMN) have what it takes to be a top stock pick for momentum investors? Let's find out.

zacks.com · 9 jul

Illumina Stock Gains 43.7% in 2026: What's Powering the Rally?

ILMN stock's 43.7% 2026 rally is fueled by strong sequencing demand, NovaSeq X momentum and progress toward higher growth and profitability.

seekingalpha.com · 9 jul

Illumina: While You Chased AI, This Healthcare Stock Built A $30B Moat

Illumina commands 90%+ market share in genomics sequencing, powering a $30B+ TAM growing at double digits with a robust razor-and-blades model. Post-GRAIL, management's renewed focus on core sequencing, cost control, and capital return is driving revenue recovery, margin expansion, and free cash flow. NovaSeq X placements and consumables pull-through are key near-term catalysts; 65%+ of consumables revenue is clinical, supporting high margins and recurring cash flows.

zacks.com · 9 jul

Here's Why Illumina (ILMN) is a Strong Momentum Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

prnewswire.com · 9 jul

Illumina appoints Michael Sullivan Chief Commercial Officer and Julie Coletti Chief Legal Officer

New leaders bring extensive leadership experience across life sciences, diagnostics, and medical technology SAN DIEGO, July 9, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced the appointment of Mike Sullivan as Chief Commercial Officer, effective July 20, 2026, and Julie Coletti as Chief Legal Officer, effective August 3, 2026. The appointments add experienced leaders to Illumina's Executive Leadership Team as the company continues advancing its strategy, serving customers, driving growth, and delivering on its mission to improve human health around the world.

zacks.com · 8 jul

Beyond Automotive: Healthcare Automation Drives the Next Leg for Robotics ETFs

Rising use of automation in healthcare is reshaping robotics ETFs as med-tech innovators gain prominence.